RxDoctor Payments Data

Eva Khavkin, MD

Psychiatry · Babylon, NYNPI 1306884978

Payments from drug & device makers

$4,681in general payments, 2019–2025

Across 50 payments — averaging $93.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • AbbVie$625
  • Avanir Pharmaceuticals, Inc.$609
  • Johnson & Johnson$278
  • E.r. Squibb & Sons, L.L.C.$146
  • plus $464 from 5 others

What the payments were for

  • Food & beverage$4,681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,681 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$176,003
Medicare patients
386
Services billed
1,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine82$122,640
RexultiBrexpiprazole63$93,220
ExelonRivastigmine60$39,898
NamzaricMemantine Hcl/Donepezil Hcl67$38,059
ZenpepLipase/Protease/Amylase34$28,715
TrintellixVortioxetine Hydrobromide45$21,044
VraylarCariprazine Hcl14$19,924
Rivastigmine177$18,982
AmbienZolpidem Tartrate23$14,261
Clonazepam621$12,904
Memantine Hcl ErMemantine Hcl194$12,584
BelsomraSuvorexant22$9,571
Lurasidone Hcl25$9,459
XanaxAlprazolam12$9,125
Seroquel XrQuetiapine Fumarate20$8,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$609$122,64082 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,460$93,22063 claims
AbbVieNamzaric, Vraylar$625$57,98381 claims
Aimmune Therapeutics, Inc.Zenpep$26$28,71534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Babylon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →